Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

Hepatitis B virus serologic markers and anti-hepatitis B vaccination in patients with diabetes

Waldemar Halota, Mirosława Muszyńska, Małgorzata Pawłowska

Med Sci Monit 2002; 8(7): CR516-519 :: ID: 510711


Background: In Poland HBV infections are mainly the result of nosocomial infections or risky behavior. Active prevention plays a crucial role in limiting such infections. Patients suffering from insulin-dependent diabetes (type 1) incur high risk of infection with hepatotropic viruses because of frequent hospitalization and blood tests. The aim of our study was to determine the frequency of occurrence of serological markers of HBV infection among patients with diabetes type 1, to evaluate the humoral response to HBV vaccine depending on dosage, and to evaluate the influence of past HBV infections on vaccination response.
Material/Methods: 299 diabetic patients were vaccinated against hepatitis B with Engerix B in two doses (20 µg or 40 µg), on a 0-1-6 month schedule. The humoral response to the vaccination was evaluated in the 5th and 8th months after the first dose of vaccine according to sex, dose and previous detection of anti-HBc in serum. Serologic markers of HBV infection were detected with the immunoenzymatic-fluorescent ELFA method, with bioMerieux tests using the VIDAS system.
Results: 98.7% of patients achieved protective anti-HBs titer after vaccination. Women responded better than men. There were no differences in mean anti-HBs concentration by vaccine dose. Patients with previous serum anti-HBc achieved anti-HBs titers (p0.00001).
Conclusions: The frequency of anti-HBc among patients with diabetes confirms the widespread risk of HBV infection in the Polish population. Diabetics should be vaccinated against hepatitis B with standard doses. Diabetics with anti-HBc in serum can be vaccinated with a single dose.

Keywords: HBV infection, diabetics, Vaccination

Add Comment 0 Comments


01 May 2024 : Editorial  

Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)

Dinah V. Parums

DOI: 10.12659/MSM.944927

Med Sci Monit 2024; 30:e944927

In Press

Clinical Research  

Differential Inflammatory Responses in Adult and Pediatric COVID-19 Patients: Implications for Long-Term Co...

Med Sci Monit In Press; DOI: 10.12659/MSM.944052  

Clinical Research  

Effectiveness of Shoulder Taping in Treating Hemiplegic Shoulder Subluxation: A Randomized Controlled Study...

Med Sci Monit In Press; DOI: 10.12659/MSM.944222  

Clinical Research  

Comparison of Fentanyl, Ketamine, and Lidocaine Combined with Propofol Anesthesia in Patients with Crohn Di...

Med Sci Monit In Press; DOI: 10.12659/MSM.944116  

Database Analysis  

ANXA5: A Key Regulator of Immune Cell Infiltration in Hepatocellular Carcinoma

Med Sci Monit In Press; DOI: 10.12659/MSM.943523  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799


14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990


16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387


01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952


Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750